Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raphael Itzykson

Showing results (81-90 of 97) with videos related to

Pageof 10
Sort By:
Blood Advances|April 25, 2018
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohortMaximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2022
Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO NetworkRaphael Itzykson, Valeria Santini, Sylvain Thepot, et al.
British Journal of Haematology|April 4, 2018
Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registriesMaría Díez-Campelo, Jose I Lorenzo, Raphael Itzykson, et al.
Haematologica|July 7, 2019
Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registryMarlijn Hoeks, Ge Yu, Saskia Langemeijer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2025
Clonal Evolution of PPM1D Mutations in the Spectrum of Myeloid DisordersDavid Fandrei, Jean Pegliasco, Florence Pasquier, et al.
Cancer Discovery|July 24, 2021
Actinomycin D Targets NPM1c-Primed Mitochondria to Restore PML-Driven Senescence in AML TherapyHsin-Chieh Wu, Domitille Rérolle, Caroline Berthier, et al.
Nature Cancer|June 6, 2022
P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemiaKevin H Lin, Justine C Rutter, Abigail Xie, et al.
Cancer Discovery|August 23, 2020
The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting TherapiesAngela Su, Frank Ling, Camille Vaganay, et al.
Nature Communications|February 25, 2016
Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agentsJane Merlevede, Nathalie Droin, Tingting Qin, et al.
Evolutionary Applications|February 12, 2013
Applying ecological and evolutionary theory to cancer: a long and winding roadFrédéric Thomas, Daniel Fisher, Philippe Fort, et al.
Pageof 10

Showing results (81-90 of 97) with videos related to

Sort By:
Pageof 10
Blood Advances|April 25, 2018
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohortMaximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2022
Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO NetworkRaphael Itzykson, Valeria Santini, Sylvain Thepot, et al.
British Journal of Haematology|April 4, 2018
Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registriesMaría Díez-Campelo, Jose I Lorenzo, Raphael Itzykson, et al.
Haematologica|July 7, 2019
Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registryMarlijn Hoeks, Ge Yu, Saskia Langemeijer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2025
Clonal Evolution of PPM1D Mutations in the Spectrum of Myeloid DisordersDavid Fandrei, Jean Pegliasco, Florence Pasquier, et al.
Cancer Discovery|July 24, 2021
Actinomycin D Targets NPM1c-Primed Mitochondria to Restore PML-Driven Senescence in AML TherapyHsin-Chieh Wu, Domitille Rérolle, Caroline Berthier, et al.
Nature Cancer|June 6, 2022
P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemiaKevin H Lin, Justine C Rutter, Abigail Xie, et al.
Cancer Discovery|August 23, 2020
The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting TherapiesAngela Su, Frank Ling, Camille Vaganay, et al.
Nature Communications|February 25, 2016
Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agentsJane Merlevede, Nathalie Droin, Tingting Qin, et al.
Evolutionary Applications|February 12, 2013
Applying ecological and evolutionary theory to cancer: a long and winding roadFrédéric Thomas, Daniel Fisher, Philippe Fort, et al.
Pageof 10